Ridinilazole

Summary

Ridinilazole (CHEMBL3753858) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including clostridium infectious disease and bacterial infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 4
• Chemistry: 388.4 Da · C24H16N6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3753858
Name	Ridinilazole
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	16659285
Molecular formula	C24H16N6
Molecular weight	388.4
InChIKey	UHQFBTAJFNVZIV-UHFFFAOYSA-N

SMILES: C1=CC2=C(C=C1C3=CC4=C(C=C3)N=C(N4)C5=CC=NC=C5)NC(=N2)C6=CC=NC=C6

IUPAC name: 2-pyridin-4-yl-6-(2-pyridin-4-yl-3H-benzimidazol-5-yl)-1H-benzimidazole

Also known as: Ridinilazol, Ridinilazole, SMT-19969, Smt19969, SMT19969, RIDINILAZOLE

Patent coverage: 58 distinct patent families (136 SureChEMBL compound mentions), from 6 matched compound structure(s). One matched structure accounts for 95 (70%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Clostridium infectious disease	2	MONDO:0024388	EFO:0009130
bacterial infectious disease	1	MONDO:0005113	EFO:0000771

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03595553	PHASE3	COMPLETED	Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
NCT04802837	PHASE3	TERMINATED	Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
NCT02092935	PHASE2	COMPLETED	A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
NCT02784002	PHASE2	COMPLETED	A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).